Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 13, 2021 08:30 ET | Source: Veru Inc.

Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer

-- Enobosarm is a novel targeted hormone drug to be evaluated in the 3rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed,...
September 20, 2021 08:30 ET | Source: Veru Inc.

Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
September 09, 2021 08:30 ET | Source: Veru Inc.

Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

MIAMI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
September 08, 2021 08:30 ET | Source: Veru Inc.

Veru to Present at Three Upcoming Healthcare Investment Conferences

MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
August 12, 2021 06:30 ET | Source: Veru Inc.

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter

--Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs— --Nine-Month FY21 Year to Date Net Revenues Increased 48% to $46M, also a Record...
July 29, 2021 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th

MIAMI, July 29, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
June 28, 2021 08:30 ET | Source: Veru Inc.

Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress

MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers,...
June 25, 2021 08:30 ET | Source: Veru Inc.

Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer

--Sabizabulin is a novel oral androgen receptor transport disruptor---- In Phase 1b/2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration...
June 10, 2021 08:30 ET | Source: Veru Inc.

Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer

--VERU-100 formulated to address the clinical limitations of currently available androgen deprivation therapy-- --The Phase 2 clinical trial is expected to be completed by 2H calendar 2021-- MIAMI,...
June 07, 2021 08:30 ET | Source: Veru Inc.

Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting

-- In Phase 2 study, enobosarm, an oral selective androgen receptor (AR) agonist, had the most significant antitumor effects in heavily pretreated AR+ER+ metastatic breast cancer subjects with ≥ 40%...